LINK PHARMA CHEM LTD.

Link Pharma Chem Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 1st, 2026, and will remain in effect until 48 hours after the declaration of the Unaudited Financial Results for the quarter ending June 30th, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The specific date for the board meeting to consider these financial results will be communicated separately.

Link Pharma Chem Ltd's board re-appointed Mr. Satish G. Thakur as Chairman and Whole-time Director for 3 years, effective June 24, 2026, subject to shareholder approval at the upcoming Annual General Meeting. Mr. Thakur has been with the company since its incorporation and has over 43 years of experience.

Link Pharma Chem Ltd. has re-appointed Mr. Rishikesh S. Thakur as Managing Director for a term of 3 years, effective from September 24, 2026, subject to shareholder approval at the upcoming Annual General Meeting. Mr. Thakur has over 15 years of experience in the chemical business and previously served as General Manager – Operations at the company. He is the son of Mr. Satish G. Thakur, Chairman & Whole-time Director of the company.

Link Pharma Chem Ltd announced audited financial results for the quarter and year ended March 31, 2026. The company reported a loss before tax of ₹49 lakhs for the quarter ended March 31, 2026, and a loss of ₹40.86 lakhs after tax. The board also approved the re-appointment of statutory, internal, and cost auditors, as well as the re-appointment of Mr. Satish G. Thakur as Chairman and Whole Time Director and Mr. Rishikesh Thakur as Managing Director.

Link Pharma Chem Ltd's audited financial results for the year ended March 31, 2026, reveal a loss of ₹102.73 lakhs. The Board of Directors approved these results along with the re-appointment of Mr. Satish G. Thakur as Chairman and Wholetime Director, and Mr. Rishikesh Thakur as Managing Director, both subject to shareholder approval. Revenue from operations stood at ₹2,743.15 lakhs for the year ended March 31, 2026.

Link Pharma Chem Ltd has announced a Board of Directors meeting scheduled for May 21, 2026, to consider and approve the audited financial results for the year ended March 31, 2026. The announcement was made to the BSE under Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The trading window has been closed since April 1, 2026, and will reopen 48 hours after the declaration of the results.

Link Pharma Chem Ltd has announced the closure of its trading window from 01st April, 2026, in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct. The trading window will remain closed until 48 hours after the declaration of Audited Financial Results for the quarter and year ending on 31st March, 2026. The date of the Board Meeting at which the results will be considered is yet to be intimated.

Link Pharma Chem Ltd. has announced its unaudited financial results for the quarter and nine months ended on 31st December 2025. The company's revenue from operations stands at Rs. 653.37 lakhs for the quarter and Rs. 2,084.27 lakhs for the nine months period. The total expenses for the quarter are Rs. 632.87 lakhs and Rs. 2,702.24 lakhs for the nine months. The company's net loss for the quarter is Rs. 18.65 lakhs and Rs. 53.923 lakhs for the nine months. The company operates under a single segment, 'Manufacture and Sale of Chemicals'. The financial results have been reviewed by the statutory auditors and approved by the Board of Directors.

Link Pharma Chem Ltd. has reported its unaudited financial results for the quarter and nine months ended on 31st December, 2025. The company's revenue from operations stands at Rs. 2,084.27 crores for the nine-month period. The net loss for the period is Rs. 18.65 crores. The company operates under a single segment, 'Manufacture and Sale of Chemicals'. The financial instruments are valued at market prices as per Ind AS 109. The new Labour Codes have been assessed and found to have no material financial impact on the company's financial statements.

Link Pharma Chem Ltd has informed the BSE that a meeting of the Board of Directors is scheduled on 14th February, 2026. The meeting will consider and approve the unaudited financial results of the Company for the quarter and nine months ended on December 31, 2025. The trading window of the Company is closed from January 1, 2026, and will open 48 hours after the declaration of the unaudited financial results.